OCX Stock Overview
A precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
OncoCyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.69 |
| 52 Week High | US$4.86 |
| 52 Week Low | US$2.08 |
| Beta | 0.83 |
| 1 Month Change | -6.92% |
| 3 Month Change | -10.63% |
| 1 Year Change | -37.00% |
| 3 Year Change | -97.44% |
| 5 Year Change | -96.37% |
| Change since IPO | -97.85% |
Recent News & Updates
Recent updates
Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28
Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?
Jan 25OncoCyte signs an at-the-market agreement to sell $50M of common stock
Jun 14Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt
Jun 02Here's What OncoCyte Corporation's (NASDAQ:OCX) Shareholder Ownership Structure Looks Like
Mar 18Shareholder Returns
| OCX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.5% | 2.3% | 1.2% |
| 1Y | -37.0% | 6.8% | 20.8% |
Return vs Industry: OCX underperformed the US Biotechs industry which returned 8.3% over the past year.
Return vs Market: OCX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| OCX volatility | |
|---|---|
| OCX Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OCX has not had significant price volatility in the past 3 months.
Volatility Over Time: OCX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 45 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests.
OncoCyte Corporation Fundamentals Summary
| OCX fundamental statistics | |
|---|---|
| Market cap | US$35.95m |
| Earnings (TTM) | -US$40.03m |
| Revenue (TTM) | US$1.38m |
26.0x
P/S Ratio-0.9x
P/E RatioIs OCX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCX income statement (TTM) | |
|---|---|
| Revenue | US$1.38m |
| Cost of Revenue | US$989.00k |
| Gross Profit | US$393.00k |
| Other Expenses | US$40.42m |
| Earnings | -US$40.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.00 |
| Gross Margin | 28.44% |
| Net Profit Margin | -2,896.60% |
| Debt/Equity Ratio | 0% |
How did OCX perform over the long term?
See historical performance and comparison